Aura Biosciences (AURA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Voting matters and shareholder proposals
Election of two Class II directors, David Johnson and Teresa Marie Bitetti, to serve until the 2029 annual meeting or until a successor is elected or qualified.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Audit committee and external auditor matters
Proposal to ratify Ernst & Young LLP as the external auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Aura Biosciences
- Bel-sar leads innovation in ocular oncology with robust data and a strong financial runway.AURA
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA27 May 2026 - Bel-sar targets early, vision-preserving cancer therapy with pivotal data expected by 2027.AURA
H.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026 - Novel dual-mechanism cancer therapy shows strong efficacy in pivotal ocular and bladder trials.AURA
Corporate presentation11 May 2026 - Firmonertinib and next-gen ADCs drive late-stage oncology pipeline with strong clinical momentum.AURA
Corporate presentation11 May 2026 - Q1 2026 net loss rose to $33.7M; cash runway extends to 2H 2028 after $299M equity raise.AURA
Q1 202611 May 2026 - CEO transition, clinical trial progress, and capital actions mark a pivotal period for the company.AURA
Proxy filing4 May 2026 - 2026 meeting to elect directors, ratify auditor, and highlight governance and compensation updates.AURA
Proxy filing20 Apr 2026 - Bel-sar delivers high tumor control and vision preservation, pioneering new standards in cancer care.AURA
Corporate presentation30 Mar 2026 - Lead trial enrollment accelerates, cash runway extends into 2027, net loss rises to $106M.AURA
Q4 202530 Mar 2026